Despite India’s rapid economic growth over the past two decades, clinical research in the field of cancer has not kept pace, according to a new study that found significant disparities in cancer research output across countries.

The study revealed that India’s growth in cancer-related clinical trials since 2001 has been largely inconsistent, indicating that economic development alone may not guarantee equitable progress in medical research. The findings also underscore broader global disparities, with low- and middle-income countries (LMICs) continuing to lag behind wealthier nations in cancer research infrastructure and clinical activity.

Researchers, including those from the Latin American Cooperative Oncology Group, noted that while the number of cancer trials worldwide has increased, most are still disproportionately concentrated in high-income countries. This imbalance persists despite growing evidence of rising cancer incidence and mortality in developing regions.

The study warned that cancer cases and deaths are projected to surge in the coming decades, with LMICs expected to shoulder a disproportionate share of the global burden. The researchers called for stronger investment in clinical trial infrastructure, international collaboration, and equitable funding to ensure that cancer research and treatment advancements benefit populations across all economic levels.